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Edited by Ga´spa´r Je´kelyAbstract Cardiovascular disease is responsible for 17 million
deaths per year but acute myocardial infarction and stroke can
be treated with thrombolytics (‘‘clot busters’’), which are plas-
minogen activators. However, despite many years of study and
huge investment from the pharmaceutical industry, clinical trials
of new drugs have often been disappointing. Part of the problem
may be our incomplete understanding of the regulation of plas-
minogen activation in vivo. We have developed precise in vitro
methods and with the application of computer simulations, we
hope to improve our understanding of plasminogen activation
to facilitate improvements in thrombolytic therapy.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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WHO ﬁgures highlight cardiovascular disease (CVD) as the
single biggest cause of mortality worldwide, estimated at 17
million deaths per annum [1]. Estimates of disability adjusted
life years for men and women, which include the burden of
the debilitating eﬀects of myocardial infarction and stroke,
are also headed by CVD. CVD aﬀects high income nations
(for example there are 270 000 heart attacks in Britain every
year) and increasingly CVD is a problem for low and middle
income nations. Developing countries accounted for 60% of
the total burden of coronary heart disease in 2002, and this ﬁg-
ure is rising rapidly. Thrombolytic therapy is a cost eﬀective
way of improving survival from myocardial infarction in devel-
oped [2] and developing countries [3]. Fibrinolysis is the bio-
chemical process underlying thrombolysis since both
processes depend on the degradation of the ﬁbrin network that
holds the blood clot together in a coronary or cerebral artery
in the case of myocardial infarction (heart attack) or ischaemic
stroke, respectively. In a simpliﬁed form, ﬁbrinolysis can be
represented as a two-step process according to Scheme 1.
The two stages are: (I) the activation of plasminogen to plas-
min by a plasminogen activator (PA) and (II) is the degrada-
tion of the structural protein, ﬁbrin, to ﬁbrin degradation*Corresponding author. Fax: +44 1707 646730.
E-mail address: clongstaﬀ@nibsc.ac.uk (C. Longstaﬀ).
0014-5793/$30.00  2005 Federation of European Biochemical Societies. Pu
doi:10.1016/j.febslet.2005.03.058products (FDP). The participants in stage (I) are assembled
on the surface of ﬁbrin ﬁbres and the propagation of plasmin
action in the circulation is limited by the potent plasma inhib-
itor system. Thrombolytic therapy, which was introduced in
the 1980s, is essentially the delivery of PA into the circulation.
From the point of view of developing and improving thrombo-
lytic therapy, the characteristics of the PA need to be opti-
mized to promote rapid clot dissolution. The only way of
doing this is to maximize the generation of plasmin (while min-
imizing the side eﬀects) and this is why the characteristics of
PAs are of overriding importance for successful therapy. How-
ever, despite many years and huge sums of money spent on
improving thrombolytic therapy though clever design of re-
combinant proteins (to date mostly serine proteases and some
plasminogen binding proteins), improvements in survival rates
have been hard fought for and so small that they are only ob-
servable in huge, and hugely expensive, clinical trials. Is it pos-
sible that some of this lack of progress is due to our incomplete
understanding of the basic enzymology and regulation of the
process of ﬁbrinolysis? Approaches to exploring this question
will be discussed below.2. A brief history of thrombolytic proteins
Historically, the ﬁrst generation of thrombolytics (e.g.,
streptokinase and urokinase) were systemic activators of plas-
minogen giving rise to large scale plasmin production in the
circulation and concomitant loss of circulating plasminogen,
ﬁbrinogen and the plasma inhibitors. Streptokinase (and
staphylokinase, see below) belong to a group of plasminogen
binding proteins secreted by invasive bacteria in order to gen-
erate plasmin and facilitate ‘‘bacterial metastasis’’ [4]. Uroki-
nase is a naturally occurring protease that can be isolated on
industrial scales from human urine, although it is present in
circulation as an inactive, single chain pro-enzyme. Second
generation thrombolytics with ﬁbrin binding domains were
produced by genetic engineering with the seemingly rational
aim of targeting the PA to a ﬁbrin clot. Thus, the development
of tissue plasminogen activator (tPA), for example, was driven
by the theory that since tPA has to bind to ﬁbrin to express sig-
niﬁcant activity, administered tPA would be targeted at the
clot and systemic plasmin generation would be limited. The
idea was that this would be a good thing as systemic loss of
plasminogen substrate would be reduced; and possibly bleed-
ing complications (for example intracranial hemorrhageblished by Elsevier B.V. All rights reserved.
Fig. 1. The domain arrangement of tPA and related variants devel-
oped as thrombolytics. Native tPA (alteplase) consists of 527 amino
acids in the domains: ﬁnger (F), growth factor (G), kringle 1 (K1),
kringle 2 (K2), and serine protease (P). The gene was cloned from
melanoma cells and is expressed in CHO cells. Fibrin binding is mostly
regulated initially via F and subsequently via K2 which binds to newly
generated C-terminal lysine residues in degrading ﬁbrin. Glycosylation
sites are present at N117 (K1), N184 (K2) and N448 (P), and there is a
fucosylation site at T61. Reteplase is a deletion variant of tPA
consisting of K2P and is produced in Escherichia coli so is not
glycosylated. Tenektaplase is modiﬁed in 3 sites with the addition of a
glycosylation site by substitution at T103N and removal of the
glycosylation site at N117Q. These substitutions improve plasma half
life while maintaining ﬁbrin binding properties. The third mutation is
KHRRR(296-299)AAAA designed to reduce the reactivity with the
speciﬁc serpin inhibitor PAI-1. Lanoteplase is another deletion variant
of tPA lacking FG domains and also the glycosylation site at N117Q
to improve plasma half life. Monteplase may be viewed as a protein
folding variant of tPA caused by the change of C84S. This substitution
leads to an unexpected rearrangement of disulﬁde bonds, loss of the
fucosylation site at T61 and altered carbohydrate at N117. Pamiteplase
has K1 deleted, again to improve plasma half life, and a site speciﬁc
change at R275E designed to maintain the molecule in the single chain
form which may improve ﬁbrin binding. Desmoteplase is the DSPAa1
variant cloned from the vampire bat and lacks the ﬁbrin binding K2
domain (though ﬁbrin binding is still mediated via the F domain).
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Scheme 1.
3304 C. Longstaﬀ, C. Thelwell / FEBS Letters 579 (2005) 3303–3309(ICH), which occurs in up to 3% of patients receiving treat-
ment) might be reduced.
Following on from tPA, the so-called third generation of
thrombolytics were engineered. The goal was improved prop-
erties in terms of longer plasma half life, or resistance to
natural inhibitors, or improved ﬁbrin binding and
‘‘zymogenicity’’, making them even more ﬁbrin speciﬁc (e.g.,
reviewed [5,6]). Many of these variants used the basic tPA tem-
plate but domains were deleted or modiﬁed with the stated aim
of improving properties. The domain arrangement of a selec-
tion of these molecules is shown in Fig. 1, including tPA (phar-
maceutical name: alteplase). In spite of the huge and rising
global burden of CVD and concomitant massive ﬁnancial
investment by the pharmaceutical industry, protein engineer-
ing of second and third generation thrombolytics may be inter-
preted as a failure. Basic scientiﬁc considerations, in vitro data
and animal studies have not been translated into signiﬁcant
improvements in outcomes in clinical trials [7,8]. This lack of
clear improvement and the much increased cost of second
and third generation thrombolytics means that streptokinase
is still the most widely used thrombolytic for the treatment
of acute myocardial infarction in many parts of the world,
including the UK for example, as it has been since the earliest
uses of thrombolytic therapy.
To date no further signiﬁcant progress has been seen with
other tPA-based thrombolytics such as reteplase, monteplase,
lanoteplase or pamiteplase for example, or chimeras such as
amediplase (the ﬁbrin binding kringle 2 of tPA fused with
the serine protease domain of uPA which has better catalytic
parameters than tPA), or other molecules such as saruplase
(single chain urokinase) or staphylokinase [6]. Despite all the
detailed investigations of protein biochemistry on these mole-
cules (reviewed [9]) the only advantage of the newer thrombo-
lytics is extended plasma half life enabling the delivery of the
drugs as a bolus injection rather than the longer infusion of
ﬁrst and second generation treatments. This may be a signiﬁ-
cant improvement in reducing the lag time from symptoms
to treatment since reteplase [10] may be given by paramedics
before arrival at hospital in 2 bolus injections and tenectaplase
as a single bolus injection [11,12]. Hence, so far the only
improvements in thrombolytic therapy relate to the pharmaco-
kinetics of the drugs, not other properties such as ﬁbrin bind-
ing or speciﬁcity, or inhibitor susceptibility. Our current
understanding of PA activity in ﬁbrin has been inadequate to
permit the successful rational design of new molecules or opti-
mized treatment regimes.3. The enzymology of ﬁbrinolysis
Scheme 1, above, is clearly a simplistic overview of the reac-
tions underlying ﬁbrinolysis and includes no suggestion of reg-ulatory mechanisms. A slightly more detailed impression of the
steps involved in plasmin generation is shown in Fig. 2. In this
case, we have split plasmin generation into 3 parallel processes
and may consider this scheme for plasmin generation with ref-
erence to tPA as the activator enzyme (PA). In (1), plasmino-
gen activation can take place in solution and does not require
Fig. 2. Scheme showing plasminogen activation reactions taking place
in a ﬁbrin clot. Reaction (1) is the generation of plasmin (Pn) from
plasminogen (Pg) catalysed by plasminogen activator (PA) taking
place in solution in the absence of ﬁbrin (F). Reaction (2) shows the
formation of a ternary complex of PA–Pg–F leading to generation of
Pn at the ﬁbrin surface. Plasmin digests ﬁbrin initially generating C-
terminal lysines in partially degraded ﬁbrin (F\) which presents
additional binding sites for PA and Pg. Eventually, ﬁbrin is degraded
to soluble ﬁbrin degradation products (FDP) as the clot is lysed.
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circulation and reaction (1) would be signiﬁcant for streptoki-
nase and urokinase, for example. The second generation
thrombolytics, such as tPA, require ﬁbrin as a cofactor to ex-
press signiﬁcant activity, and plasmin generation would be
concentrated in reactions (2) and (3). Here, ﬁbrin is shown
as a template and a ternary complex of enzyme (PA), substrate
plasminogen (Pg) and cofactor ﬁbrin (F) is formed, promoting
the generation of plasmin (Pn).
Initially, plasminogen is bound to native ﬁbrin (F) with low
aﬃnity in the 107–105 M range [9,13] to a limited number of
binding sites formed by internal lysine residues. tPA also binds
poorly at this stage, although published Kd values are highly
variable, e.g. [13–15]. The ﬁnger domain of tPA is implicated
in this form of binding [16]. However, the plasmin generated
in reaction (2) is then able to begin the digestion of ﬁbrin by
cleaving at lysine and arginine residues. The result is partially
digested ﬁbrin (F\) which has new C-terminal lysine residues
that form highly eﬀective binding sites, via kringle domains
present in both tPA and plasminogen. Therefore, stage (3) in
Fig. 1 represents a positive feedback mechanism. The aﬃnity
of the C-terminal residues for tPA and plasminogen kringle
binding sites is in the same range as initial binding but the
number of binding sites is now increased and plasminogen acti-
vation is observed to accelerate [17,18].
As mentioned above, tPA will be poorly active in reaction
(1), at least at low doses. Reaction (1) will be more signiﬁcant
at higher pharmacological doses which may reach into the
107 M range, several thousand fold higher than the normal
circulating concentration. Reaction (1) will also be stimulated
to some degree by ﬁbrinogen and ﬁbrin(ogen) fragments [19].
However, there will be more activity from reaction (2) and
an acceleration in reaction (3) in the presence of ﬁbrin. Other
thrombolytic agents will have diﬀerent proﬁles. Streptokinase
and urokinase are systemic PAs and will be active in circula-
tion (reaction 1) and in the ﬁbrin clot (reactions 2 and 3). Third
generation thrombolytics may demonstrate diﬀerent reactivity
proﬁles, as discussed below.3.1. Experimental approaches
Typically, most ﬁbrinolysis assays have monitored the two
processes shown in Scheme 1 together by clotting ﬁbrinogen,
in the presence of plasminogen and PA to produce a clot rap-
idly and then observing the slower phase of ﬁbrin lysis. This
gives a global measure of ﬁbrinolysis. Many approaches to
measurement have been used, for instance gross changes in clot
physical structure reﬂected in the ability of a clot in a tube to
support a glass bead [20] or retain trapped bubbles [21], both
endpoint methods. Alternatively ﬁbrin opacity is a convenient
marker and may be measured as lysis zones on plates, or
changes in OD in microtitre plate formats [22–25] or another
automated device [26]. Most of these methods use puriﬁed
components, though modiﬁed plasma can be used [27]. Alter-
native methods use chemically modiﬁed ﬁbrinogen with radio-
chemical detection [28,29], or chromogenic [30] or ﬂuorogenic
detection [31] of released degradation products. Methods using
chromogenic substrates for plasmin have been developed in the
presence of homogenized ﬁbrin [32,33] or where ﬁbrin is re-
moved before OD measurement [34] or correction made for ﬁ-
brin absorbance [35]. Soluble ﬁbrinogen fragments may be
used in some circumstances [36], but these may not be exactlycomparable to assays that include some form of solid ﬁbrin
[37]. These methods may readily be used to measure PA activ-
ity in comparison with a standard preparation. Sometimes
plasminogen substrate concentration can be varied and appar-
ent Km and kcat values will be reported, but such values need to
be treated with caution since they are method speciﬁc and not
easily comparable from one laboratory to another [38]. Fur-
thermore, the meaning of Km and kcat in these assays is not
straightforward. Where enzyme and substrate bind to a tem-
plate which catalyses the reaction, varying the concentration
of one component aﬀects the equilibrium of the ternary
complex and the reaction does not follow simple Michaelis–
Menten kinetics [15].
As a way forward, we have shown it is possible to separate
reaction (I) from reaction (II) (Scheme 1) for most PAs by
manipulating the ionic strength of the clotting stage, to pro-
duce clear ﬁbrin. In this way reaction (I) can be studied in iso-
lation, but in a system containing ﬁbrin. This is achieved by
ﬁrst of all mixing ﬁbrinogen, thrombin and plasminogen to
create a transparent clot in a microtitre plate to which PA
can subsequently be added (after 30 min in our method). If
plasmin-sensitive chromogenic substrate is added at the same
time, the plasmin generated as the PA enters the clot and
encounters plasminogen can be easily monitored. A detailed
description of the method has been published elsewhere [39].
Such a method is quite simple in design and at its simplest
may be viewed as a chromogenic reaction taking place on a
pad of (invisible) ﬁbrin. The components are all puriﬁed and
hence it is possible that the reaction can be standardized to al-
low comparison of results between laboratories. Compared
with most other methods cited above, the two-step approach
where clotting is allowed to complete before PA is added is
not common. However, it may be argued that this is more rep-
resentative of the situation in vivo where thrombolytics are gi-
ven to act on pre-existing clots and must attack the clot from
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a forming clot [40]. Studies comparing tPA and streptokinase,
for example, indicate that in this system the relative activities
on a mole for mole basis reﬂect the doses given during stan-
dard infusions for acute myocardial infarction [39]. Many
other in vitro assay systems seem to exaggerate the diﬀerences
between ﬁbrin speciﬁc and non-speciﬁc agents (e.g. [31])
whereas such diﬀerences are not reﬂected in clinical trials [8]
(see below).
3.2. Modelling ﬁbrinolysis
Although this two-step chromogenic method has some
advantages and some disadvantages over previous methods,
one major advantage is that the activity of the PA in this de-
ﬁned system may be expressed in SI units. Knowing the kinetic
parameters of the generated plasmin on the chromogenic sub-
strate (and the eﬀect of competition of the ﬁbrin on plasmin),
we can calculate the rate of plasmin generation in M s1. Cru-
cially, this allows us to begin to assemble computer simulations
of the reactions shown in Fig. 2, which can be tested in vitro
and reﬁned. Kinetic and binding parameters shown in Fig. 2
can be explored and predictions made on how the properties
of thrombolytic drugs (PAs) might be improved to speed up
thrombolysis in vivo.
Several simple ‘‘oﬀ the shelf’’ computer programs exist that
enable reaction pathways to be simulated and data ﬁtted by
numerical integration after supplying reaction schemes in sim-
ple notation. Excellent examples are PLAS [41] and Gepasi
[42–44]. Such programs are intended for the simulation of ex-
tended metabolic pathways, so from this point of view at least
the reactions shown in Fig. 2 should not pose a problem. A
simple reaction sequence of reactions, that might represent
the behaviour of streptokinase for example, is illustrated in
Scheme 2.
Reactions (i) and (ii) represent the reaction of plasmin (E)
with chromogenic substrate (S) used in our method and re-
quire an input for the apparent Km and kcat for the reaction,
respectively. Similarly, reactions (iii) and (iv) (where G is plas-
minogen and A is activator) require apparent Km and kcat val-
ues for the plasminogen activation reaction. Reaction (v)
accounts for the competition of the ﬁbrin substrate with reac-
tion (i), and can be studied separately.
The kinetics of plasminogen activation by a range of activa-
tors has been investigated using our method previously
[37,39,45]. This has allowed us to determine apparent values
for Km and kcat for these activators in this system and provide
working estimates for the parameters needed for reactions (i)–
(v) in Scheme 2. If these constants are then fed back into the
model shown in Scheme 2, data can be generated in silico
for activator (streptokinase and tPA) concentrations and plas-
minogen concentrations that match closely data collected in
earlier in vitro studies [37,45]. Although this is rather circular,i. E + S = ES
ii.  ES -> E + P
iii. G + A = GA
iv. GA -> E + A
v. E + F = EF
Scheme 2. Fibrinolysis with streptokinase.it does show that the simple model seems to be enough to ac-
count for the results obtained using our precise method, over
the initial phase of plasminogen activation and everything is
internally consistent. This is not always the case, but the devi-
ations from the simple Scheme 2 are valuable in probing details
of mechanisms of activation.
The next stage in gaining a better understanding of the
behaviour of PAs in a ﬁbrin milieu is to extend the simple
model shown in Scheme 2 to reﬂect the additional steps shown
in Fig. 2. Thus, the generation of C-terminal lysines (and the
formation of F\) need to be included as well as the equilibria
between plasminogen and activator with F and F\, and real
microscopic parameters for Km and kcat in this deﬁned system.
When all this is done the eﬀects of improving binding charac-
teristics or kinetic parameters in activators can be explored in a
quantitative way and give pointers to improvements in throm-
bolytic therapy, as discussed in more detail below. The in vitro
system we use will also be helpful in these studies as it is pos-
sible to study binding and equilibrium reactions, for example
by studying ﬂuorescently labelled plasminogen and PA binding
to our transparent ﬁbrin clots. A series of ﬂuorescent proteins
based on the jelly ﬁsh green ﬂuorescent protein are being con-
structed to perform binding and FRET studies. Furthermore,
we can isolate reactions (1)–(3) in Fig. 2. For instance, soluble
lysine analogs such as aminohexanoic acid or tranexamic acid
can be used to block kringle binding in plasminogen and PAs.
Furthermore, incorporating carboxypepdidase B (CPB) into
the clot to degrade C-terminal lysines as they form allows us
to study reactions (1) and (2), while eliminating reaction (3),
shown in Fig. 2. This will also enable us to probe the signiﬁ-
cance of C-terminal lysine generation on the activity of diﬀer-
ent activators and assess the likely physiological signiﬁcance of
the naturally occurring inhibitor of ﬁbrinolysis, carboxypepti-
dase U or TAFI [46–48]. Conversely, ﬁbrinogen can be pre-
treated with plasmin to generate C-terminal lysine residues
and produce a ﬁbrin after clotting that resembles F\, enabling
reaction (3) in Fig. 2 to be studied in isolation. Our in vitro
method works well under these conditions as shown by sample
data in Fig. 3. The eﬀects on apparent Km of C-terminal lysine
generation can be readily assessed and the good quality of the
data is clear. Similar work (not shown) clearly indicates the
overriding importance of C-terminal lysines and reaction (3)
for some activators. These include reteplase (which binds via
kringle 2 to C-terminal lysines) and staphylokinase which
seems to have a requirement for plasminogen bound to C-ter-
minal lysine residues [49].3.3. Complications in ﬁbrinolysis
As outlined above, we have some simple methodology for
studying ﬁbrinolysis and can assemble simple reaction
schemes that account for some results. However, there are
some signiﬁcant complications that need to be tackled. First
of all, it is clear that ﬁbrinolysis takes place in a heteroge-
neous system in which solid ﬁbrin acts as a template and
substrate with soluble PA and plasminogen. Therefore, some
caution and simpliﬁcations are needed when dealing with
concepts such as concentration of binding sites and equilib-
ria. Having said this, it might be possible to make useful
progress by applying the same approaches that have been
used in the study of plasminogen activation on cell surfaces
[50–52].
Fig. 3. Initial rates of activation of plasminogen by tPA using the 2
stage in vitro method described in the text and [39]. Fibrin was
prepared in the normal way, or incorporating CBP, or from ﬁbrinogen
pretreated with plasmin to mimic plasminogen activation in reaction
(2) and (3) in Fig. 2, respectively. The situation with normal ﬁbrin
represents a transition between the two stages during the experiment.
Clearly the addition of CPB to the clot and elimination of C-terminal
lysines during ﬁbrin degradation leads to a signiﬁcant increase in
apparent Km for the activation of plasminogen by tPA, caused by
reduced availability of binding sites compared to the situation in the
other curves.
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due to the distribution of reactants. The way our in vitro meth-
od works involves adding PA to a preformed clot containing
plasminogen (which is the way thrombolytic therapy works
too). Although, it may be the case that activators such as strep-
tokinase and urokinase diﬀuse freely into the clot, it is know
that molecules with ﬁbrin aﬃnity such as tPA and variants
in Fig. 1, form a highly concentrated reactive zone that moves
through the clot [53]. However, at its simplest, our method
measures only initial rates of plasmin production (we measure
OD changes up to 0.1) before any substrate depletion becomes
signiﬁcant. This allows us to investigate some important ques-
tions. Where longer time courses are of interest, it is relatively
easy to include terms into our models by expanding Scheme 2,
for the diﬀusion of chromogenic substrate and PA through the
clot, for example.
The pathway shown in Fig. 2, also omits several feedback
loops, for example the formation of partially degraded ‘‘lys-
plasminogen’’ with greater reactivity and higher binding aﬃn-
ity for ﬁbrin (and contested signiﬁcance). tPA exists in single
chain or two chain form (though unusually for a serine prote-
ase in coagulation and ﬁbrinolysis the single chain form is ac-
tive and not a zymogen), and there are conﬂicting reports on
the signiﬁcance of this proteolytic modiﬁcation, which is also
catalysed by plasmin. Signiﬁcantly, the presence of inhibitors
is ignored in Fig. 2, such as a2-plasmin inhibitor and PAI-1,
an inhibitor of tPA and urokinase, but these will be important
in vivo. There are several other aspects of our in vitro assay
method in its simplest form that may not adequately reﬂect
the in vivo situation, including the presence of cells and pro-
teins released from cells [54–57] or immunoglobulins [58] or
phospholipids [59]. However, there is scope to add possibleeﬀectors to our system to investigate the importance of these
components to plasminogen activation kinetics. Ultimately,
another aim will be to include a model for the digestion of ﬁ-
brin (phase II in Scheme 1) to assemble a complete picture of
what thrombolysis might look like in vivo [60].4. Conclusions and future prospects
4.1. Can we improve ﬁbrinolysis and thrombolysis
Right from the ﬁrst clinical trials comparing streptokinase
with tPA, it was apparent that the clinical improvements
achieved were at best marginal and required huge and expen-
sive clinical trials to establish a diﬀerence that was statistically
signiﬁcant [7]. Even more disturbing were the ﬁndings that the
so-called ‘‘ﬁbrin speciﬁc’’ agents produced higher numbers of
fatal and serious ICH than streptokinase (reviewed [8]). This
was observed from early trials with tPA [61,62] and continued
or even worsened for later thrombolytics such lanoteplase
[63,64]. One problem may be that the development of third
generation thrombolytics has not been guided by any serious
modelling of what changes in ﬁbrin binding characteristics or
enzyme parameters might mean for rates of plasminogen acti-
vation. In some cases, there has been a simple philosophy of
emphasizing ﬁbrin binding (e.g., tenectaplase, pamiteplase);
whereas other molecules have coped with reduced ﬁbrin bind-
ing apparently without detrimental consequences (e.g., retep-
lase, monteplase). The developers of desmoteplase would
highlight the extreme ﬁbrin speciﬁcity of this agent as it is
not stimulated by ﬁbrinogen, unlike other tPA-based activa-
tors. However, it is inevitable that the assay systems used by
workers involved with a particular agent will be chosen to
illustrate superiority over a competing variant. In the ﬁnal
analysis, judged by the gold standard of the clinical trial, the
results with new agents have been disappointing [65].
However, improved understanding of the regulation of ﬁbri-
nolysis may lead to better PAs and might lead to better treat-
ment using mixtures of PAs, for example. There may be
optimized mixtures of ﬁbrin speciﬁc and non-ﬁbrin speciﬁc
PA that could be identiﬁed using computer models. Mixtures
of PA with diﬀerent properties seem to have evolved in the case
of the vampire bat for example, which produces a mix of PAs
to prevent blood clotting during feeding. One form is currently
under development for the treatment of ischaemic stroke (des-
moteplase), but the mixture present naturally in the saliva of
the bat may be an example of an ‘‘experiment of nature’’ that
has evolved to optimize ﬁbrinolysis rates. In a similar way, it
may be possible to improve properties of a single molecule
by combining domains from diﬀerent proteins to promote clot
penetration, as is the rationale behind amediplase [66]. Addi-
tional advantages may be expected from combining members
of the plasmin system with ﬁbrinolytic proteinases from leuko-
cytes [67].
Exploration of ﬁbrinolysis in vitro and in silico may also re-
veal some possible explanations that account for resistance to
thrombolytics of aged clots [8] and thus extend the therapeutic
window without increasing ICH. Or it may be possible to tai-
lor treatment according to risk factors in a patients history,
their sex or age (since older patients are at much greater risk
of cerebral bleeding) [68,69]. Finally, it may also be possible
to improve current thrombolytic treatment for ischaemic
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stroke and only within 6 h of onset of symptoms [70]. Bearing
in mind ischaemic stroke accounts for 80% of all strokes, inci-
dence increases in ageing populations, and there are so few
treatments currently available, improvements here would have
a major impact on mortality and morbidity [71].
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